Dr. David Matthew Kurtz, MD

Dr. Kurtz practices at Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University.

Dr. Kurtz's NPI, 1770875353, was assigned on May 13, 2011. Dr. Kurtz graduated from Mayo Clinic Alix School of Medicine - Rochester in 2009. Dr. Kurtz holds California license A114549.

Dr. Kurtz's primary practice is Stanford Hospital at 300 Pasteur Drive, at 300 Pasteur Drive, Stanford, CA 94305 in Santa Clara County. The practice phone is (650) 723-4000.

Dr. Kurtz's primary practice is Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University. The medical group on file is Stanford Health Care. Dmand AI also links Dr. Kurtz to 1 more hospital and 1 medical group, each named with a free account. Dr. Kurtz's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kurtz practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Kurtz's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Kurtz is board certified in internal medicine by the American Board of Internal Medicine. Dr. Kurtz is licensed in California.

Dmand AI lists chronic anemia, chronic leukemia and lymphoma among the conditions Dr. Kurtz treats.

CMS data shows 100 Medicare services from Dr. Kurtz across 1 procedure code in 2024, all of them office visits, for 52 Medicare patients. Medicare paid $14,046 for them.

CMS counts 52 Medicare patients who saw Dr. Kurtz in 2024. The largest group is 75 to 84, with 27 patients. 75% of them have high cholesterol, and 60% have high blood pressure. 21% are also on Medicaid. Their average risk score is 2.58, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kurtz's median patient age at 68, with 45% women.

In 2024, Dr. Kurtz wrote 23 Medicare Part D claims. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $166,577 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Kurtz for performance year 2024, reported as part of a group. Dr. Kurtz accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kurtz as offering telehealth.

Dmand AI links 45 papers to Dr. Kurtz, published from 2008 to 2025. 2016 was the busiest year, with 4. The most frequent topics are Circulating Tumor DNA, Biomarkers, Tumor and Lymphoma, Large B-Cell, Diffuse. Dr. Kurtz has published most often in Blood Adv. Dr. Kurtz's most frequent co-authors are Arash Ash Alizadeh, MD, PhD, Maximilian Diehn, MD, PhD and Brian Jeffrey Sworder, MD.

CMS Open Payments shows 4 general payments to Dr. Kurtz from 1 drug or device company from 2018 to 2019. Speaker and faculty fees make up the largest share, 95% of the total. Genentech, Inc. paid the most, $721. It also lists 4 research payments totaling $6,769 from 2020 to 2024.

Dr. Kurtz graduated from Mayo Clinic Alix School of Medicine - Rochester in 2009.

Dr. Kurtz is in network with 6 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.